- Home
- CMCL vs FENC Comparison
CMCL vs FENC Comparison
Compare CMCL & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | FENC |
|---|---|---|
| Founded | 1992 | 1996 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.3M | 266.4M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CMCL | FENC |
|---|---|---|
| Price | $22.42 | $7.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $28.00 | $15.00 |
| AVG Volume (30 Days) | ★ 201.6K | 126.3K |
| Earning Date | 03-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | $57.27 | N/A |
| Revenue Next Year | $28.69 | $70.78 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $10.65 | $4.68 |
| 52 Week High | $38.75 | $9.92 |
Technical Indicators
Market Signals| Indicator | CMCL | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 41.18 |
| Support Level | $18.54 | N/A |
| Resistance Level | $24.49 | $8.27 |
| Average True Range (ATR) | 1.31 | 0.43 |
| MACD | -0.59 | -0.07 |
| Stochastic Oscillator | 14.85 | 8.57 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.